Validation of NAD+ Measurements for Human Clinical Studies

Validation of NAD+ Measurements for Human Clinical Studies: Multi-method Inter-laboratory Standardization

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07416786

Enrollment

Registered

2026-02-18

Start date

2026-09-01

Completion date

2028-07-31

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Brief summary

The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).

Detailed description

This is an open-label, nonrandomized study, primary outcome is to correlate blood and tissue measurements of NAD+ and metabolites. Investigators will recruit 12 men and 12 women aged 18-35 years and 12 men/12 women aged 70 years or older. Whole blood, serum and urine will be collected and MRS measurements performed at baseline and 30 days for in vivo determinations of nicotinamide adenine dinucleotide (NAD) and its metabolites. After baseline measurements, participants will take 1000 mcg of NR orally daily for 30 days. Baseline measurements will be repeated on days 29 and 30. Assessors of outcomes will be blinded to study status of participants.

Interventions

DIETARY_SUPPLEMENTOral NR Supplementation

Oral Nicotinamide Riboside (NR)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Masking description

related to blood, urine measurement and MRS interpretation.

Intervention model description

2 age groups, both to corrrelate blood and tissue measurements of NAD+ and metabolites.

Eligibility

Sex/Gender

ALL

Age

18 Years to 110 Years

Healthy volunteers

Yes

Inclusion criteria

* Male or female age18-35 years or 70 years or older, healthy * if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation). * No known sensitivity to NR * No use of niacin, blood thinners or chemotherapy agents * HbA1c below 8.5% and not diabetec requiring insulin. * Not using/taking corticosteroids * No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease * No contraindication to MRI * Not Pregnant, lactating, or planning to become pregnant during participation * Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation). * not taking/ undergoing another investigational drug or other intervention within the past 30 days.

Design outcomes

Primary

Measure	Time frame	Description
Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI	Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)	NAD level will be assessed in brain MRI
NAD measurement of calf MRI	Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)	NAD level in calf MRI

Secondary

Measure	Time frame	Description
Serum NAD metabolites	Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with NR	Measurement of serum metabolites of Nicotinamide adenine dinucleotide
Urine NAD metabolites	Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)	Measurement of urine NAD metabolites

Countries

United States

Contacts

CONTACTDamodar Reddy

cdamodar@pennmedicine.upenn.edu215-898-9357

CONTACTJordan Maddox, BA

jordan.maddox@pennmedicine.upenn.edu215-898-3694

PRINCIPAL_INVESTIGATORRavinder Reddy, Ph.D.

University of Pennsylvania

STUDY_DIRECTORJoseph A. Baur, Ph.D.